Biohaven Q2 net loss $3.64/sh; pipeline highlights MoDE degrader data and FDA alignment for BHV-8000

Biohaven Ltd.

2024-Q2 EPS reported -$5.93

Net loss of $319.8M ($3.64/sh) in Q2 2024 vs $1.32/sh in Q2 2023; cash ~$440M.
R&D expense $314.8M includes $171.9M non-cash milestone/royalty buyback to Knopp for Kv7 platform.
MoDE platform: Phase 1 BHV-1300 showed dose-dependent IgG reduction, no SAEs; SC formulation had 44% higher exposure vs IV.
BHV-8000 (TYK2/JAK1) Phase 1 completed; FDA feedback enables registrational programs for Parkinson's and prevention of ARIA.
Taldefgrobep alfa: Phase 2 obesity trial and Phase 3 SMA topline data expected in H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.